J&J touts PhII data in rare blood disorder as it plots a pivotal study
Of the mothers on J&J’s candidate for a rare blood disorder that occurs during pregnancy, more than half achieved a live birth with no intrauterine transfusions (IUTs), the company said Monday.
The pharma giant’s Janssen unit uncorked the data months after announcing a positive topline Phase II readout in those at high risk of early-onset severe (EOS) hemolytic disease of the fetus and newborn (HDFN). The candidate, nipocalimab, is the lead drug from J&J’s $6.5 billion Momenta buyout.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
